866929-82-0

Basic information

• Product Name: 5-bromo-2-[(tert-butyl-dimethyl-silanyl)-ethynyl]-pyridine
• Synonyms: 5-bromo-2-[(tert-butyl-dimethyl-silanyl)-ethynyl]-pyridine
• CAS NO: 866929-82-0
• Molecular Formula: C₁₃H₁₈BrNSi
• Molecular Weight: 296
• Mol File: 866929-82-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-bromo-2-[(tert-butyl-dimethyl-silanyl)-ethynyl]-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-[(tert-butyl-dimethyl-silanyl)-ethynyl]-pyridine(866929-82-0)
• EPA Substance Registry System: 5-bromo-2-[(tert-butyl-dimethyl-silanyl)-ethynyl]-pyridine(866929-82-0)

Safety Data

• Hazardous Substances Data: 866929-82-0(Hazardous Substances Data)

Upstream product

• 86318-61-8 (tert-butyldimethylsilyl)acetylene 
• 223463-13-6 2-iodo-5-bromopyridine 
• 624-28-2 2,5-dibromopyridine 
• 87290-98-0 (3,3-dimethylbut-1-yn-1-yl)dimethylsilane 

Downstream Products

• 866931-05-7 cis-1-{6-[(tert-butyl-dimethyl-silanyl)-ethynyl]-pyridin-3-yl}-4-methyl-cyclohexanol 
• 866930-62-3 trans-1-{6-[(tert-butyl-dimethyl-silanyl)-ethynyl]-pyridin-3-yl}-4-methyl-cyclohexanol 
• 1363438-79-2 2-((tert-Butyldimethylsilyl)ethynyl)-5-p-tolylpyridine 
• 1488359-60-9 C₅₅H₅₃BrN₅O₄Pt⁽¹⁺⁾*C₇H₇O₃S^(1-) 
• 111770-86-6 2-ethynyl-5-bromo-pyridine 
• 1488359-58-5 2-(1-(2-phenylethyl)-1H-1,2,3-triazol-4-yl)-5-bromopyridine 
• 866929-83-1 2-[(tert-butyl-dimethyl-silanyl)-ethynyl]-5-(4-chloro-phenyl)-pyridine 

Relevant articles and documents

Acid-base responsive switching between 3+1 and 2+2 platinum complexes

We report that the acid-base induced changes to a cyclometallated platinum complex can be used to drive the exchange of accompanying ligands with different denticities.

New compounds, pharmaceutical compositions and uses thereof

The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds having MCH-receptor antagonistic activity, which are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS

The invention relates to individual alkyne compounds with an antagonistic action against the MCH-receptor. Said compounds are suitable for producing medicaments for the treatment of metabolic disorders and/or eating disorders, in particular adiposity and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

NOVEL ALKYNE COMPOUNDS EXHIBITING AN MCH ANTAGONISTIC EFFECT AND DRUGS CONTAINING SAID COMPOUNDS

The invention relates to an alkyne compound of general formula (I) in which A, B, W, X, Y, Z, R and R groups and residuals have the meanings given in claim 1. Drugs containing at least one type of inventive alkyne are also disclosed. The inventive drugs exhibiting an MCH-receptor antagonistic activity are suitable for treating metabolic disturbances and/or eating disorders, in particular adiposity, bulimia, anorexia, hyperphagia and diabetes.

NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS

The invention relates to alkyne compounds of general formula (I), in which groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings cited in Claim 1. The invention also relates to medicaments containing at least one inventive alkyne. The MCH receptor antagonistic effect renders the inventive medicaments suitable for treating metabolic disorders and/or eating disorders, in particular, obesity and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to alkyne compounds of general formula I wherein the groups and radicals A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one alkyne according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS CONTAINING SAID COMPOUNDS

The invention relates to alkyne compounds of general formula (I), in which the groups and radicals A, B, W, X, Y, Z, R1 and R2 are defined as cited in claim 1. The invention also relates to medicaments containing at least one inventive alkyne. As a result of the antagonistic action against the MCH-receptor, the inventive medicaments are suitable for treating metabolic disorders and/or eating disorders, in particular adiposity and diabetes.